Home Page Settlements $55M Settlement Awarded Against J&J in Second Talc-Cancer Lawsuit
$55M Settlement Awarded Against J&J in Second Talc-Cancer Lawsuit
This is a settlement for the Johnson & Johnson lawsuit.
Santa Clara, CA: A $55 million settlement has been levelled against Johnson & Johnson (J&J) by a jury hearing the case of a woman who alleges her use of the company' talc-powder products for feminine hygiene caused her to develop ovarian cancer.
This is second verdict in a row against J&J in talc-cancer lawsuits. J&J plans to appeal. The company is facing some 1200 such lawsuit all claiming the company failed to adequately warning consumers about its talc-based products' cancer risks.
The trial took three weeks, and returned the verdict in favor of Gloria Ristesund in a day. She was awarded $5 million in compensatory damages and $50 million in punitive damages.
According to her suit, Ristesund used J&J' talc-based powder products, which include the well-known Baby Powder and Shower to Shower Powder, on her genitals for decades. According to her lawyers, she was diagnosed with ovarian cancer and had to undergo a hysterectomy and related surgeries. Her cancer is now in remission.
The verdict in the first J&J talc-cancer lawsuit awarded $72 million to the family of a woman who died from ovarian cancer. She had also used the talc powder for feminine hygiene for years.
Legal HelpIf you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.
Published on May-3-16
READ MORE [ Consumer Fraud Settlements and Legal News ]
READ MORE [ Defective Products Settlements and Legal News ]
READ MORE [ Personal Injury Settlements and Legal News ]
I had four operations for ovarian cancer in 1977. 8, 79, and 80. I was on chemo for one year.
J & J never contacted me,a nd I continued using talc. I have since come down with ovarian cancer again. I'm devastated, and in a lot of pain. I had 1/3rd or my bowel removed and face more surgeries. Damn them.
ADD YOUR COMMENT ON THIS ISSUE